更正：肌肉减少症对转移性去势抵抗性前列腺癌男性患者临床结局的影响。
Correction: The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
作者信息
Papadopoulos Efthymios, Wong Andy Kin On, Law Sharon Hiu Ching, Zhang Lindsey Ze Jing, Breunis Henriette, Emmenegger Urban, Alibhai Shabbir M H
出版信息
PLoS One. 2024 Nov 19;19(11):e0314372. doi: 10.1371/journal.pone.0314372. eCollection 2024.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0286381.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0286381。]
相似文献
1
Correction: The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
PLoS One. 2024 Nov 19;19(11):e0314372. doi: 10.1371/journal.pone.0314372. eCollection 2024.
2
Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
J Urol. 2021 Mar;205(3):800-805. doi: 10.1097/JU.0000000000001428. Epub 2020 Oct 20.
3
The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
PLoS One. 2023 Jun 1;18(6):e0286381. doi: 10.1371/journal.pone.0286381. eCollection 2023.
4
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
PLoS One. 2021 Dec 31;16(12):e0262326. doi: 10.1371/journal.pone.0262326. eCollection 2021.
5
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
PLoS One. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709. eCollection 2018.
6
Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Clin Nutr ESPEN. 2016 Jun;13:e39-e45. doi: 10.1016/j.clnesp.2016.04.001. Epub 2016 May 6.
7
Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.
Int Braz J Urol. 2020 Jan-Feb;46(1):42-52. doi: 10.1590/S1677-5538.IBJU.2019.0225.
8
Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.
Can Urol Assoc J. 2024 Dec;18(12):405-412. doi: 10.5489/cuaj.8803.
9
Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer.
Urol Pract. 2014 May;1(1):2-6. doi: 10.1016/j.urpr.2014.02.014. Epub 2014 Mar 4.
10
Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.
Urol Pract. 2021 Jan;8(1):112-118. doi: 10.1097/UPJ.0000000000000166. Epub 2020 May 29.
本文引用的文献
1
The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
PLoS One. 2023 Jun 1;18(6):e0286381. doi: 10.1371/journal.pone.0286381. eCollection 2023.
Zotero 插件